Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Wednesday, July 22, 2026 1 min read
Key Takeaway: Kairos Pharma has entered a strategic collaboration with Bayer to assess the efficacy of ENV-105, a novel CD105/BMP signaling inhibitor, in conjunction with Bayer's XOFIGO for treating metastatic castration-resistant prostate cancer. This partnership aims to enhance treatment options for patients suffering from this challenging condition, particularly those with bone metastases.
Market Sentiment Analysis
POSITIVE FACTORS
Strategic collaboration with Bayer enhances research capabilities.
ENV-105 is a first-in-class treatment targeting CD105/BMP signaling.
Focus on metastatic castration-resistant prostate cancer is crucial.
Potential to improve outcomes for patients with bone involvement.
Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)---- $KAPA #Bayer--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced a strategic collaboration with Bayer to evaluate Kairos Pharma’s lead antibody ENV-105 (carotuximab), a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer’s XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. Kairos Pharma’s current programs with
Frequently Asked Questions
What is the focus of the collaboration between Kairos and Bayer?
The collaboration aims to evaluate ENV-105 in combination with XOFIGO for metastatic prostate cancer.
What is ENV-105?
ENV-105 is a first-in-class CD105/BMP signaling inhibitor developed by Kairos Pharma.
What type of cancer is targeted in this collaboration?
The collaboration focuses on metastatic castration-resistant prostate cancer.
What is XOFIGO?
XOFIGO is a treatment developed by Bayer, specifically for bone metastases in prostate cancer.